Can bimekizumab be used to treat uveitis

Bimekizumab (Bimekizumab) is a type of dual-targeted biological agent that simultaneously blocks IL-17A and IL-17F . It has shown quite impressive efficacy in diseases such as plaque psoriasis and psoriatic arthritis. Since many immune-mediated diseases have intersections in inflammatory pathways, some patients are also concerned about whether bicizumab can be used to treat uveitis, especially whether the previous experience with IL-17 drugs can be extended to the field of ocular inflammation. Currently, bicizumab is not approved for the treatment of uveitis, and there are no clinical guidelines to support its use in this indication.

Uveitis is a complex ocular immune-inflammatory disease. Its pathogenesis involves T cell activation, abnormal cytokine circuits, and the accumulation of multiple inflammatory factors. IL-17A has indeed been found to be involved in the pathological process in some subtypes of uveitis, so the IL-17 pathway was once considered to have potential therapeutic value. However, the clinical results of currently approved IL-17A inhibitors (such as secukinumab) in the field of uveitis are not stable enough, with large differences in efficacy and limited response in some patients, making the positioning of the IL-17 pathway in uveitis more cautious. Therefore, although it has a stronger mechanism and more targets than chitilizumab, it is not sufficient to infer that it can exert the same effect in uveitis.

Some basic research is evaluating the role of IL-17F in ocular inflammation, but the level of evidence currently does not reach a level that can support clinical use. At the same time, the treatment of uveitis still relies mainly on more evidence-based treatment options such as glucocorticoids, immunosuppressants, and TNF-α inhibitors. An ideal uveitis biologic would require good ocular tissue penetration while controlling inflammation, and these conditions have not yet been demonstrated with bichizumab.

Reference: https://www.drugs.com/bimekizumab.html